LOS ANGELES--(BUSINESS WIRE)--
CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, announced that Executive Vice President and Chief Medical Officer Daniel Levitt, M.D., Ph.D., will give the Grand Rounds presentation today to the prestigious Department of Hematology and Oncology at LSU Medical School in New Orleans. The presentation, “The Diversity of Albumin-Linked Cancer Drugs,” will focus on advancements in CytRx’s program with aldoxorubicin, an improved version of the widely used chemotherapeutic doxorubicin.
Systemically delivered doxorubicin is dose-limited to a level below its maximum anti-tumor capabilities due to its toxicity, including potential damage to the heart muscle. Aldoxorubicin combines doxorubicin with a novel albumin-binding linker platform technology that concentrates doxorubicin at the site of the tumor, thereby reducing the toxic side effects associated with systemic delivery. Clinical trials demonstrated that 3.5 to 4 times the standard dose of native doxorubicin could be safely administered with aldoxorubicin. CytRx is currently conducting an international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcomas, and plans to initiate a Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy.
CytRx holds the exclusive worldwide rights to aldoxorubicin, as well as option rights to the linker platform technology.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is conducting an international Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company is initiating a Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene. For more information about CytRx Corporation, visit www.cytrx.com.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx’s clinical trials, the risk that any future human testing of aldoxorubicin, the Company’s linker technology and other drug candidates might not produce results similar to those seen in past human or animal testing, risks related to CytRx’s ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 3 clinical development of aldoxorubicin, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- Clinical trials